Skip to main navigation
  • Home
  • About Us
    • Overview
    • Our Story
      • Our Parent Company
    • Mission and Values
    • Our People and Culture
      • Organization & Governance
      • Our Employees
      • Our Communities
      • 1000 Cranes of Hope
    • Patient Advocacy
    • Policies & Practices
      • Corporate Compliance
    • Grants and Donations
    • Sunshine Act / Open Payments Program
    • Supplier Diversity
  • Our Pipeline
    • Overview
    • Our Pipeline
    • Clinical Trials
      • Information for Patients
      • The INSIGHT-MM Study
    • Preclinical Drug Compound Request Program
    • IISR Program
  • Our Medicines
    • Overview
    • ADCETRIS
    • ALUNBRIG
    • ICLUSIG
    • MEPACT
    • NINLARO
    • VECTIBIX
    • VELCADE
    • Access to Investigational Medicines
  • News & Media
    • Overview
    • News Releases
    • Social Media
    • Business Development
      • Alliances & Partnerships
      • Investors
  • Careers
Takeda Oncology
We Aspire to Cure Cancer®
  • Home
  • About Us
    • Overview
    • Our Story
      • Our Parent Company
    • Mission and Values
    • Our People and Culture
      • Global Oncology Leadership Team
      • Our Employees
      • Our Communities
      • 1000 Cranes of Hope
    • Patient Advocacy
    • Policies & Practices
      • Corporate Compliance
    • Grants and Donations
    • Sunshine Act / Open Payments Program
    • Supplier Information
  • Our Pipeline
    • Overview
    • Investigational Studies & Access
  • Our Medicines
    • Overview
    • ADCETRIS
    • ALUNBRIG
    • ICLUSIG
    • MEPACT
    • NINLARO
    • VECTIBIX
    • VELCADE
    • Expanded Access to Investigational Medicines
  • News & Media
    • Overview
    • News Releases
    • Social Media
    • Business Development
      • Alliances & Partnerships
      • Investors
  • Careers
CONTACT USTERMS OF USEPRIVACY POLICYTAKEDA.com
  • Home
  • About Us
    • Overview
    • Our Story
      • Our Parent Company
    • Mission and Values
    • Our People and Culture
      • Organization & Governance
      • Our Employees
      • Our Communities
      • 1000 Cranes of Hope
    • Patient Advocacy
    • Policies & Practices
      • Corporate Compliance
    • Grants and Donations
    • Sunshine Act / Open Payments Program
    • Supplier Diversity
  • Our Science
    • Overview
    • Our Science
    • Clinical Trials
      • Information for Patients
      • The INSIGHT-MM Study
    • Preclinical Drug Compound Request Program
    • IISR Program
  • Our Medicines
    • Overview
    • ADCETRIS
    • MEPACT
    • NINLARO
    • VECTIBIX
    • VELCADE
    • Access to Investigational Medicines
  • News & Media
    • Overview
    • News Releases
    • Social Media
    • Business Development
      • Alliances & Partnerships
      • Investors
  • Careers

NEWS RELEASES

Keyword Search

DateTitle
Jan 19, 2021
Takeda to Hold Investor Call on January 29 During World Conference on Lung Cancer
Contact Us
Terms of Use
Privacy Policy
Takeda.com
  • LinkedIn
  • YouTube
  • Twitter
  • Facebook
  • Instagram

All trademarks are property of their respective owners.

©2021 Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Group Company Limited.
All rights reserved. 04/18

 
close

You Are Leaving Takeda Oncology

You are now leaving takedaoncology.com. Links to sites outside of takedaoncology.com are provided as a resource to the viewer. takedaoncology.com accepts no responsibility for the linked sites that takedaoncology.com has no control over.

To stay on the current Web site, click "Cancel."

Continue       Cancel

Interacting with Takeda Oncology on Social Media

Definition of Social Media

Takeda Oncology recognizes the importance of social media channels in the communication space. However, in embracing these channels, we aim to engage responsibly. Below, we have outlined our current active channels as well our terms and guidelines for interacting with us on these channels. Current channels in which Takeda Oncology participates:

  • Twitter:https://twitter.com/takedaoncology
  • Facebook:https://www.facebook.com/takedaoncology
  • YouTube:https://www.youtube.com/takedaoncology
  • LinkedIn:https://www.linkedin.com/company/takedaoncology
  • Instagram:http://www.instagram.com/takedaoncology

Other services may be added. Check back occasionally to see all of the channels we support.

These channels were created and are managed by Takeda Oncology. Their purpose is to educate the public about our company, mission, values as well as the diseases we aspire to cure and the populations we serve. The content posted by Takeda Oncology is for informational and educational purposes only and is NOT intended to be a substitute for professional medical advice.

Mentions, comments, likes, favorites and retweets are welcomed! However, please note, the pharmaceutical industry is a highly regulated one and as a result we may not be allowed to respond to "@mentions" and replies that:

  • Include profanity, defamatory, libelous, offensive, abusive, discriminatory or demeaning content (including images, videos and links)
  • Are disparaging, threatening, condone violence or illegal behavior
  • Offer health or medical advice
  • Are commercial or advertising, e.g. sell products and services, or recruit fans and followers
  • Are spam
  • Are excessively repetitive and/or disruptive to the community
  • Are questions directly related to financial, legal, regulatory, confidential information or medical issues
  • Violate the social media platform rules

Please note that accounts that Takeda Oncology follows/interacts with or accounts that follow/interact with us on our various channels are not an indication of Takeda Oncology's endorsement of these accounts or the content they produce. Additionally, favorites, likes, comments and/or retweets do not indicate endorsement.

Takeda Oncology may provide links or references to other websites as part of its social content. We claim no responsibility for the accuracy or content of such other sites and shall not be liable for any damages or injury arising from that content.

Please do not use these channels to report adverse events or medical side effects. If you believe that you have experienced any medical side effects or reactions from a Takeda Oncology product you should consult your physician, pharmacist or other healthcare professional immediately. You can also report these to us directly by using the following contact information:

  • For ALUNBRIG: 1-844-A-1POINT (1-844-217-6468) or GlobalOncologyMedinfo@takeda.com
  • For ADCETRIS, Mepact or Pipeline: 1-844-ONC-TKDA (1-844-662-8532) or GlobalOncologyMedinfo@takeda.com
  • For ICLUSIG: 1-844-T-1POINT (1-844-817-6468) or GlobalOncologyMedinfo@takeda.com
  • For NINLARO: 1-844-N-1POINT (1-844-617-6468) or GlobalOncologyMedinfo@takeda.com
  • For VELCADE: 1-866-VELCADE (1-866-835-2233) or GlobalOncologyMedinfo@takeda.com

 

Questions, adverse events and product complaints for non-oncology products may be directed to 1-877-TAKEDA7 (1-877-825-3327) or medicalinformation@takeda.com

We will do our best to answer your comments and questions; however, there may be some things we cannot address, such as questions directly related to financial, legal, regulatory, confidential information, or medical issues. In scenarios when Takeda Oncology cannot post or respond to your comment, we will send a private message to you explaining why.

Thank you for your interest in connecting with us on social media — we look forward to hearing from you and sharing more about our work in the fight against cancer.

DISCLAIMER

Takeda Oncology does not endorse any user or associated products and services of any social media user that interacts with our profiles. Takeda Oncology may link to an external website for interest or convenience. Takeda Oncology claims no responsibility for the content of sites over which we have no control, and are not liable for any damages or injury arising from that content. Takeda Oncology reserves all rights relating to our social media profiles and properties, including discontinuing the Page, removing unwanted connections, responding to any questions or comments, and removing or modifying any content posted to the profile.

Continue       Cancel